Moberg Pharma: Expecting phase 3 results
Research Note
2020-05-14
07:20
Redeye maintains its valuation of Moberg Pharma after the Q3 report. The decisive catalyst for our re-valuation of the case and share will be the upcoming result from the phase III MOB-015 study.
GA
Gergana Almquist
Disclosures and disclaimers